{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:32:58Z","timestamp":1773297178732,"version":"3.50.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia\/lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease. (Blood. 2004;104:3355-3357)<\/jats:p>","DOI":"10.1182\/blood-2003-11-3922","type":"journal-article","created":{"date-parts":[[2004,6,18]],"date-time":"2004-06-18T00:19:19Z","timestamp":1087517959000},"page":"3355-3357","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"John E.","family":"Janik","sequence":"first","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"McDonald","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Grant","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223313664500_REF1","doi-asserted-by":"crossref","unstructured":"Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74: 1678-1689.","DOI":"10.1182\/blood.V74.5.1678.1678"},{"key":"2020021223313664500_REF2","doi-asserted-by":"crossref","unstructured":"Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299: 65-67.","DOI":"10.1038\/299065a0"},{"key":"2020021223313664500_REF3","doi-asserted-by":"crossref","unstructured":"Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96: 3681-3695.","DOI":"10.1182\/blood.V96.12.3681"},{"key":"2020021223313664500_REF4","doi-asserted-by":"crossref","unstructured":"Bekkenk MW, Geelen FA, Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95: 3653-3661.","DOI":"10.1182\/blood.V95.12.3653"},{"key":"2020021223313664500_REF5","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89: 3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2020021223313664500_REF6","doi-asserted-by":"crossref","unstructured":"Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer. 2000;88: 186-197.","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5"},{"key":"2020021223313664500_REF7","doi-asserted-by":"crossref","unstructured":"Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14: 219-228.","DOI":"10.1038\/modpathol.3880289"},{"key":"2020021223313664500_REF8","doi-asserted-by":"crossref","unstructured":"Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [letter]. Science. 1995;267: 316-317.","DOI":"10.1126\/science.267.5196.316-b"},{"key":"2020021223313664500_REF9","unstructured":"Pittaluga S, Wiodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23\/ALK rearrangements. Am J Pathol. 1997;151: 343-351."},{"key":"2020021223313664500_REF10","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Ott G, Pulford K, et al. t(1;2)(q21; p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood. 1999;94: 362-364.","DOI":"10.1182\/blood.V94.1.362.413a45_362_364"},{"key":"2020021223313664500_REF11","doi-asserted-by":"crossref","unstructured":"Wlodarska I, Wolf-Peeters C, Falini B, et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood. 1998;92: 2688-2695.","DOI":"10.1182\/blood.V92.8.2688"},{"key":"2020021223313664500_REF12","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93: 3913-3921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"2020021223313664500_REF13","unstructured":"Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93: 2697-2706."},{"key":"2020021223313664500_REF14","doi-asserted-by":"crossref","unstructured":"Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol. 1997;15: 3355-3362.","DOI":"10.1200\/JCO.1997.15.11.3355"},{"key":"2020021223313664500_REF15","doi-asserted-by":"crossref","unstructured":"Nadali G, Vinante F, Stein H, et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol. 1995;13: 1355-1360.","DOI":"10.1200\/JCO.1995.13.6.1355"},{"key":"2020021223313664500_REF16","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Pileri S, Bendandi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol. 1998;16: 1532-1537.","DOI":"10.1200\/JCO.1998.16.4.1532"},{"key":"2020021223313664500_REF17","doi-asserted-by":"crossref","unstructured":"Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113: 619-627.","DOI":"10.7326\/0003-4819-113-8-619"},{"key":"2020021223313664500_REF18","doi-asserted-by":"crossref","unstructured":"Richards JM, Mick R, Latta JM, et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia [see comments]. Blood. 1990;76: 1941-1945.","DOI":"10.1182\/blood.V76.10.1941.1941"},{"key":"2020021223313664500_REF19","unstructured":"Arun B, Curti BD, Longo DL, et al. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am. 2000;6: 21-24."},{"key":"2020021223313664500_REF20","doi-asserted-by":"crossref","unstructured":"Steis RG, Marcon L, Clark J, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988;71: 1304-1309.","DOI":"10.1182\/blood.V71.5.1304.1304"},{"key":"2020021223313664500_REF21","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84: 1361-1392.","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"2020021223313664500_REF22","doi-asserted-by":"crossref","unstructured":"Carbone A, Gloghini A, De Re V, Tamaro P, Boiocchi M, Volpe R. Histopathologic, immunophenotypic, and genotypic analysis of Ki-1 anaplastic large cell lymphomas that express histiocyte-associated antigens. Cancer. 1990;66: 2547-2556.","DOI":"10.1002\/1097-0142(19901215)66:12<2547::AID-CNCR2820661217>3.0.CO;2-6"},{"key":"2020021223313664500_REF23","unstructured":"Gutierrez ME, Grossbard ML, Little RF, et al. Dose-adjusted EPOCH chemotherapy and rituximab (EPOCH-R): an effective regimen in poor prognosis aggressive B-cell non-Hodgkin's lymphoma [abstract 95]. Proc Am Soc Clin Oncol. 2000;19: 26."},{"key":"2020021223313664500_REF24","doi-asserted-by":"crossref","unstructured":"Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99: 2685-2693.","DOI":"10.1182\/blood.V99.8.2685"},{"key":"2020021223313664500_REF25","doi-asserted-by":"crossref","unstructured":"Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96: 398-404.","DOI":"10.1182\/blood.V96.2.398"},{"key":"2020021223313664500_REF26","doi-asserted-by":"crossref","unstructured":"Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96: 4307-4312.","DOI":"10.1182\/blood.V96.13.4307"},{"key":"2020021223313664500_REF27","unstructured":"Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 1995;55: 5335-5341."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3355\/1703137\/zh802204003355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3355\/1703137\/zh802204003355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T21:41:17Z","timestamp":1682718077000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/10\/3355\/18724\/Elevated-serumsoluble-interleukin2-receptor-levels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-11-3922","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}